RxDoctor Payments Data

John Andenoro, MD

Urology · Kalispell, MTNPI 1518058551

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Neotract Inc. at 50.3% of the total. Reporting peaked in 2019 at $1,637 and has fallen 81.4% since, to $304 in 2025.

$2,565in general payments, 2019–2025

Across 62 payments — averaging $41.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • Astellas Pharma US Inc$311
  • Johnson & Johnson$145
  • AbbVie$129
  • Davol Inc.$114
  • Boston Scientific$80
  • plus $497 from 19 others

What the payments were for

  • Travel & lodging$1,12644%
  • Food & beverage$1,22948%
  • Education$2108%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,565 in reported general payments places this provider in the 60th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$86,579
Medicare patients
315
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron19$14,310
MyrbetriqMirabegron15$12,052
Tamsulosin Hcl142$1,660
Methenamine Hippurate21$908
Solifenacin Succinate38$893
Finasteride54$772
Oxybutynin Chloride67$513
Doxycycline Hyclate14$439
Megestrol Acetate11$297
Cephalexin69$210
Ciprofloxacin Hcl32$184
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$160
Tramadol Hcl56$115
Ibuprofen13$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$27$14,31019 claims
Astellas Pharma US IncMyrbetriq$311$12,05215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 45 urology providers in Montana.

Other urology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →